Press releases


17 Jun 2021

Last patient recruited to Guard Therapeutics’ phase 1b study of the investigational drug ROSgard

Guard Therapeutics announces today that all 12 patients have been included in the company’s clinical phase 1b study of ROSgard, which is being conducted in people undergoing open heart surgery who have additional risk factors for acute kidney injury. The study is being conducted at the University Hospital in Münster, Germany. Top-line results are expected to be presented in September 2021.

Read more
31 May 2021

Guard Therapeutics establishes a scientific committee with prominent international physicians and researchers in cardiothoracic surgery, intensive care and nephrology

Guard Therapeutics today announces that the company has established an external Scientific Advisory Committee (SAC) initially consisting of five global experts. The committee’s main task in the near future will be to contribute their expertise in the final design of the planned phase 2 study of the company’s investigational drug ROSgard in patients undergoing cardiac surgery.

Read more
09 Apr 2021  ·  Regulatory information

Guard Therapeutics receives an Intention to Grant notice in Europe for ROSgard

Guard Therapeutics AB (publ.) today announces that the company has received an Intention to Grant notice from the European Patent Office (EPO) for a patent application concerning its biological investigational drug ROSgard as a product, including its medical use. The next step in the process is a formal EPO approval, which provides a patent protection until 2037.

Read more
07 Apr 2021

Guard Therapeutics obtains a granted patent from USPTO concerning ROSgard as product

Guard Therapeutics AB (publ.) today announces that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application no. 16/085,500 directed to the biological investigational drug ROSgard as product (composition of matter). The granted patent follows the Notice of Allowance that was issued and communicated in December 2020.

Read more
19 Mar 2021

First patient dosed in Guard Therapeutics’ phase 1b study of company’s investigational drug ROSgard

Guard Therapeutics today announces that the first patient has been dosed in a phase 1b study of the company’s investigational drug ROSgard. The study is being conducted in patients undergoing open heart surgery who have additional risk factors for acute kidney injury. The phase 1b study is being conducted at Münster University Hospital in Germany.

Read more
15 Feb 2021  ·  Regulatory information

Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations

Guard Therapeutics today announces that Sara Thuresson has been recruited to a newly created position as Head of Clinical Operations. She held a similar position at Oncopeptides before joining Guard Therapeutics and will take up her new post on 24 May 2021.

Read more
11 Feb 2021

Guard Therapeutics patent granted in Australia

Guard Therapeutics has obtained patent protection in Australia for their biological investigational drug ROSgard, both as product and for its use in medicine.

Read more
29 Dec 2020  ·  Regulatory information

Guard Therapeutics completes successful pre-IND meeting with FDA

Guard Therapeutics today announces that the company has completed a pre-IND meeting with the US Food and Drug Administration and has received positive feedback on its planned clinical development programme for its investigational drug ROSgard. This is an important validation of the quality of the project and is a significant step towards an application to include American study centres in future clinical studies (Investigational New Drug Application, IND).

Read more
28 Dec 2020  ·  Regulatory information

Guard Therapeutics appoints Ann-Kristin Myde as Head of Global Project Management

Guard Therapeutics today announces that Ann-Kristin Myde has been appointed new Head of Global Project Management for the company. She will take up her post on 1 April 2021.

Read more
11 Dec 2020  ·  Regulatory information

Guard Therapeutics receives Notice of Allowance from USPTO for ROSgard

Guard Therapeutics AB (publ.) today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for company’s patent application 16/085,500 directed to the biological investigational drug ROSgard as product (composition of matter). A formal approval is expected shortly, and if granted the patent is valid until 2037. The Notice of Allowance further strengthens Guard Therapeutics' patent portfolio and improves market exclusivity for ROSgard in one of the company’s key markets.

Read more

We are dedicated to developing tomorrow’s drugs against oxidative stress, helping millions of people to a better life by preventing and treating serious kidney diseases. ROSgard, our biological drug candidate, mimics the body’s own powerful defense system against oxidative stress. Designed with a natural “homing” to the kidneys, ROSgard prevents kidney damage by protecting, cleaning and repairing the exposed cells and tissues.

Mail Address

Guard Therapeutics AB
Box 5216
102 45 Stockholm, Sweden

Visiting Address

Guard Therapeutics
Nybrogatan 34, 2 tr
114 39 Stockholm, Sweden

Telephone

+46 (0)8 670 65 51

E-mail

info@guardtherapeutics.com